Prodromal Schedule of Activities (Years 0 - 5)

Visit Number		SC (SPECT)	BL (Clinic)	R01	V04	R04	V06	R06	V08	R08	V10	R10	V12	[b]Transition Activities	[ll]Event Driven Modified Visit
Assessment	**[**]Timepoint**	**-60 days**	**0**	**6 mths**	**12 (Y1)**	**18 mths**	**24 (Y2)**	**30 mths**	**36 (Y3)**	**42 mths**	**48 (Y4)**	**54 mths**	**60 (Y5)**	---	---
Consent Activities															
Documentation of Prodromal Screening Consent		X													
Documentation of Informed Consent			X	As Needed										X	
Continuing Consent					X		X		X		X		X		
Research Proxy Designation			X	As Needed										X	
Consent to share contact information			X	As Needed										X	
Informed Consent Tracking Log		X	X	As Needed											
Pre-Screening Activities															
Prodromal History		X													
Olfactory Testing (UPSIT)		p[g]													
General Activities															
Demographics		X												X	
Family History		X												X	
Socio-Economics		X												X	
Physical Examination			X												
Vital Signs (Height and Weight BL + Annually)			X		X		X		X		X		X		
Review Inclusion/Exclusion Criteria		I	I												
Program Assessment			X	X	X	X	X	X	X	X	X	X	X		
Visit Status		X	X	X	X	X	X	X	X	X	X	X	X		
Screen Fail		As Needed												As Needed	
Conclusion of Study Participation				As Needed											
Neurological/Motor Assessments															
Participant Motor Function Questionnaire			P		P		P		P		P		P		
Freezing and Falls			X		X		X		X		X		X		
Neurological Examination			I		I		I		I		I		I		
Initiation of Dopaminergic Therapy				X	X	X	X	X	X	X	X	X	X		
MDS-UPDRS Part Ia			I	I	I	I	I	I	I	I	I	I	I		
MDS-UPDRS Part Ib and Part II			P	P	P	P	P	P	P	P	P	P	P		
MDS-UPDRS Part III Treatment Determination/Motor Exam/Hoehn & Yahr[a,d,e]			I	I	I	I	I	I	I	I	I	I	I		
MDS-UPDRS Repeat Part III/Hoehn & Yahr[a,d,e]					I		I		I		I		I		
MDS-UPDRS Part IV[d]				I	I	I	I	I	I	I	I	I	I		
Modified Schwab & England ADL			I	I	I	I	I	I	I	I	I	I	I		
Features of Parkinsonism			I	I	I	I	I	I	I	I	I	I	I		
Other Clinical Features			I	I	I	I	I	I	I	I	I	I	I		
Primary Research Diagnosis			I	I	I	I	I	I	I	I	I	I	I		
Clinical Global Impression (CGI)			I		I		I		I		I		I		
Clinical Diagnosis			X	X	X	X	X	X	X	X	X	X	X		
Non-Motor Assessments															

Prodromal Schedule of Activities (Years 0 - 5)

Visit Number	SC (SPECT)	BL (Clinic)	R01	V04	R04	V06	R06	V08	R08	V10	R10	V12	[b]Transition Activities	[H]Event Driven Modified Visit
Assessment **[**]Timepoint**	**-60 days**	**0**	**6 mths**	**12 (Y1)**	**18 mths**	**24 (Y2)**	**30 mths**	**36 (Y3)**	**42 mths**	**48 (Y4)**	**54 mths**	**60 (Y5)**	---	---
Olfactory Testing (UPSIT)				P		P				P				
REM Sleep Behavior Disorder Screening Questionnaire		P		P		P		P		P		P		
Epworth Sleepiness Scale		P		P		P		P		P		P		
SCOPA-AUT		P		P		P		P		P		P		
Participant Global Impression (PGI)		P		P		P		P		P		P		
Neuro QoL		P		P		P		P		P		P		
Cognitive Assessments														
Montreal Cognitive Assessment*		X		X		X		X		X		X		
Clock Drawing*		X		X		X		X		X		X		
Lexical Fluency*		X		X		X		X		X		X		
Hopkins Verbal Learning Test-Revised*		X		X		X		X		X		X		
Benton Judgment of Line Orientation*		X		X		X		X		X		X		
Modified Semantic Fluency (Animals only)*		X		X		X		X		X		X		
Letter Number Sequencing*		X		X		X		X		X		X		
Symbol Digit Modalities Test*		X		X		X		X		X		X		
Trail Making Test (A and B)*		X		X		X		X		X		X		
Modified Boston Naming Test*		X		X		X		X		X		X		
Cognitive Change		P		P		P		P		P		P		
Cognitive Categorization		I		I		I		I		I		I		
Neuropsychological Assessments														
State-Trait Anxiety Inventory for Adults		P		P		P		P		P		P		
Geriatric Depression Scale		P		P		P		P		P		P		
QUIP		P		P		P		P		P		P		
Clinical and Biological Samples														
Clinical Lab blood sample	X	X[j]												
Research Biosamples	X[M]	X		X		X		X		X		X		
Lumbar puncture		X		X		X		X		X		X		
Skin biopsy[f]	X	X[j]				X				X			X[c]	
Imaging Activities														
Pregnancy Test (prior to tracer injection), if applicable	X			X		X				X				
Dopamine Imaging	X			X		X				X				
MRI		X		X		X				X				
Safety and General Health														
[#]Adverse Events	X	X		X		X		X		X		X		
Adverse Event Telephone Assessment	X	X		X		X		X		X		X		
Current Medical Conditions Review	As Needed	X	X	X	X	X	X	X	X	X	X	X		
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X		
Participation in Other Studies	As Needed													

Prodromal Schedule of Activities (Years 0 - 5)

Visit Number		SC (SPECT)	BL (Clinic)	R01	V04	R04	V06	R06	V08	R08	V10	R10	V12	[b]Transition Activities	[H]Event Driven Modified Visit
Assessment	**[**]Timepoint**	**-60 days**	**0**	**6 mths**	**12 (Y1)**	**18 mths**	**24 (Y2)**	**30 mths**	**36 (Y3)**	**42 mths**	**48 (Y4)**	**54 mths**	**60 (Y5)**	---	---
LEDD Concomitant Medication Log		As Needed													
Surgery for PD Log				As Needed											
Report of Pregnancy		As Needed													

I = Investigator (or trained designee) completed assessment

P = Participant completed assessment

X = Investigator or Coordinator completed assessment (or as otherwise delegated)

R0X Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability not assessed for Out of Clinic or Remote "R" visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all previously enrolled participants transitioning into-new database at first visit only

c =-Previously enrolled participants transitioning to new database may be asked to have skin biopsy. If not done at first visit, may be conducted at a subsequent in person visit.

d = Investigator or Coordinator may complete treatment and timing information.

e = If the participant is on levodopa, dopamine agonists, or has had DBS, the MDS-UPDRS Part III should be performed in the OFF and ON state.

f = Skin biopsy will be conducted at participating sites.

g= Performed for sites recruiting participants not referred from Screening Core

H= see protocol section 11 for modification of visit schedule due to New Clinical Diagnosis, Need for PD Therapy or withdrawal from study

j = Do not collect at Baseline Visit if collected at Screening Visit

M = Whole blood sample collection is optional at Screening visit, as feasible by the site

*Completed on paper source first, and then scores entered into EDC

**Window of +45 days either side of Target Visit Date

Adverse events collected only day of and 2-3 business days post Dopamine Imaging, LP and skin biopsy per protocol.

As needed assessments can be located under the Event Driven category in EDC